Kornimate/medical-research-clean huggingface dataset:
pain trajectories in severe persistent inguinal post-herniorrhaphy pain

Conditions: Chronic Pain

Summary: severe persistent postsurgical pain (ppp) remains a major healthcare challenge. in the third most common surgical procedure in the uk, inguinal herniorrhaphy, including 85,000 surgeries in 2015, an estimated 1,500 to 3,000 patients will annually develop severe ppp. while the trajectory of ppp is generally considered a continuation of the acute post-surgery pain, recent data suggest the condition may develop with a delayed onset. the present study evaluated pain-trajectories in a consecutive cohort referred to a tertiary ppp-center. explanatory variables based on individual psychometric, sensory and surgical profiles were analysed.

severe persistent post-surgical pain (ppp) is a prevalent medical problem leading to impairment of physical and psycho-social functions in a large number of individuals.severe ppp may significantly influence 4-8% of the surgical population, depending primarily on the surgical procedure and technique, but also patient-related pre-surgical factors.updated criteria for ppp have recently been suggested. inguinal herniorrhaphy qualifies for ppp-research due to a high surgical volume. paradoxically, while the surgery is considered a minor procedure with limited tissue damage it is carried out in a territory with abundant nerve and vascular supply, and, complex musculoskeletal functions essential for locomotor actions. persistent pain after inguinal herniorrhaphy may develop after a seemingly successful surgical procedure, and, is seen in a severe form in 2-4% of the patients associated with significant deterioration of the health-related quality of life. the transition process from acute to persistent pain may be more complex than previously assumed, making the study of temporal pain trajectories interesting. based on clinical experience from a nationwide research center in ppp following inguinal herniorrhaphy, the authors decided first, to perform a prospective exploratory cohort study examining graphical pain charts by planimetrics, attempting to construct a valid statistical sub-classification of the trajectories. secondly, the relationship between the sub-classification of the trajectories, and, potential explanatory variables, based on individual profiles of pain, psychometrics, quantitative sensory testing, and surgical procedures, were analysed, using principal component analysis and logistic regression models.

Eligibility criteria:
inclusion criteria: * patients with severe persistent pain (\>6 mo) after groin hernia repair referred to our center for ppp exclusion criteria: * unable to cooperate with the sensory examinations

Keywords: inguinal herniorrhaphy hernia persistent postsurgical pain long term follow up quantitative sensory testing (qst) pain trajectory explanatory variables
efficacy of fractional er:yag laser in lupus erythematosus scars

Conditions: Lupus Erythematosus, Cutaneous

Summary: cutaneous lupus erythematosus (cle) is a chronic autoimmune connective tissue disease with a prevalence of 14.6 - 73.2/100,000, predominantly in women in mid adulthood. cutaneous lesions occur in about 75-80% of patients with systemic lupus erythematodes.these lesions unfortunately and invariably lead to significant scarring and postinflammatory hypo- and hyperpigmentation. several studies have reported that laser treatments in patients with cle have a positive effect and safety. however, only few case reports exist about the effect of ablative lasers such as carbon dioxide (co2) and erbium-doped yttrium aluminum garnet (er:yag) lasers in cle scarring. although no study shows a flare-up of cle after laser treatment of the scars, many physicians are afraid of treating these often stigmatizing scars. considering the huge psychological impact of facial scaring on quality of life, it is essential to explore and assess the value of already well-established treatment options for the management of scars also in patients with cutaneous lupus erythematodes. hereby the study seeks the subjective and objective improvement of the cle-scars after treatment with fractional er:yag laser compared to control (untreated) areas.


Eligibility criteria:
inclusion criteria: * informed consent * skin type i-iv * presence of \>1 scar due to cle at one localisation * stable disease (without or with permanent therapy \>3months) exclusion criteria: * history of adverse events related to ablative fractional laser therapy * ablative resurfacing within the last 6 months on the scar * pregnant or breast feeding women * intake of isotretinoin in the last 6 month * intention to become pregnant during the course of the study * any scar treatment in the last 3 month before inclusion

Keywords: lupus laser co2 er:yag
comparative outcome measures of patients receiving acute renal therapy study

Conditions: End Stage Kidney Disease; End Stage Renal Disease; Acute Kidney Injury

Summary: retrospective, multicenter, comparative, post-market study of the tablo hemodialysis system in hospitalized participants with end-stage renal disease or acute kidney injury.


Eligibility criteria:
inclusion criteria: * participant is 18 years of age. * participant weighs ≥ 34kg. * participant was hospitalized and had dialysis dependent end-stage renal disease or acute kidney injury and was prescribed acute intermittent renal replacement therapy. exclusion criteria: * treatments isolated to ultrafiltration only. * any documented condition the physician feels would prevent the participant from successful inclusion in the study.

Keywords: tablo outset medical esrd aki
management of sleep apnoea syndrome (sas) in patients with vasovagal syncope (vvs)

Conditions: Syncope, Vasovagal; Sleep Apnea Syndromes

Summary: this is a multi-centre, registry-based study whose primary objective is to evaluate the effect of treatment for sleep apnoea syndrome (sas) on the number of syncope/malaise episodes in a population suffering from both idiopathic, recurrent vasovagal syncope/malaises and sas.

treatment for sleep apnoea syndrome includes continuous positive airway pressure (cpap) or a mandibular advancement device (mad). additional routine follow-up includes 24 hour holter monitoring on a yearly basis, polysomnography on a yearly basis, multiple sleep latency tests, table tilt tests.

Eligibility criteria:
inclusion criteria: * obstructive sleep apnoea syndrome (\>15 respiratory micro awakenings per hour of sleep) with an indication for treatment * recurring vasovagal syncope episodes defined as follows: at least three vasovagal syncopes during the last two years - or- symptoms of orthostatic intolerance occurring in the last 6 months (symptoms are triggered by orthostatism and can include malaises without loss of consciousness, asthenia, dizziness, visual disturbances, tinnitus, palpitations, headache, limitations of physical activity) exclusion criteria: * pathology that may explain syncope symptoms * cardiopathy * known disautonomia * hypotension of known origin * adrenal insufficiency * thyroid disorder * history of sudden death in a first degree family member
ag2037 in treating patients with advanced, metastatic, or recurrent solid tumors

Conditions: Unspecified Adult Solid Tumor, Protocol Specific

Summary: rationale: drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. purpose: phase i trial to study the effectiveness of ag2037 in treating patients who have advanced, metastatic, or recurrent solid tumors.

objectives: * determine the maximum tolerated dose and dose-limiting toxic effects of ag2037 in patients with advanced, metastatic, or recurrent solid tumor. * determine the safety and tolerance of this drug in these patients. * assess the pharmacokinetics of this drug in these patients. * document any antitumor effects of this drug in these patients. outline: this is a dose-escalation, multicenter study. patients receive ag2037 iv weekly on weeks 1-3. treatment repeats every 4 weeks for up to 6 courses in the absence of disease progression or unacceptable toxicity. cohorts of 3-6 patients receive escalating doses of ag2037 until the maximum tolerated dose (mtd) is determined. the mtd is defined as the dose preceding that at which at least 2 of 6 patients experience dose-limiting toxicity. patients are followed weekly for 4 weeks. projected accrual: a total of 18-60 patients will be accrued for this study.

Eligibility criteria:
disease characteristics: * histologically or cytologically confirmed solid tumor * advanced, metastatic, or recurrent disease * no curative therapy exists * measurable or evaluable disease patient characteristics: age: * 18 and over performance status: * who 0-2 life expectancy: * at least 3 months hematopoietic: * absolute granulocyte count at least 1,500/mm\^3 * platelet count at least 100,000/mm\^3 * hemoglobin at least 9 g/dl hepatic: * bilirubin no greater than 1.5 mg/dl (unless due to gilbert's syndrome) * sgot or sgpt no greater than 2 times upper limit of normal (uln) (5 times uln if liver metastases present) renal: * creatinine no greater than 1.5 mg/dl * creatinine clearance at least 60 ml/min other: * no unstable or severe concurrent medical condition that would preclude study participation * no sociological or familial condition that would preclude study compliance * no psychological or addictive disorder that would preclude study compliance * not pregnant or nursing * negative pregnancy test * fertile patients must use effective contraception prior concurrent therapy: biologic therapy: * not specified chemotherapy: * at least 4 weeks since prior chemotherapy (6 weeks for nitrosourea or mitomycin) and recovered endocrine therapy: * not specified radiotherapy: * at least 4 weeks since prior radiotherapy and recovered * no prior radiotherapy to more than 40% of bone marrow surgery: * not specified other: * at least 2 weeks since prior blood transfusions * at least 4 weeks since prior investigational agent and recovered * no prior glycinamide ribonucleotide formyltransferase (garft) inhibitor * no concurrent extradietary folate supplements * no concurrent allopurinol * no other concurrent anticancer or investigational agents

Keywords: unspecified adult solid tumor, protocol specific
epirubicin and docetaxel in the treatment of patients with metastatic breast cancer

Conditions: Breast Cancer

Summary: the epirubicin/docetaxel combination is one of the most active and best tolerated taxane/anthracycline combinations. in this phase ii trial, we will further evaluate the feasibility, safety and effectiveness of the docetaxel/epirubicin combination, when administered as first-line treatment for metastatic breast cancer.

upon determination of eligibility, all patients will receive: docetaxel + epirubicin both drugs will be repeated at 21-day intervals

Eligibility criteria:
inclusion criteria: to be included in this study, you must meet the following criteria: * metastatic breast cancer confirmed by biopsy. * received no previous chemotherapy for metastatic breast cancer. * prior hormonal therapy is acceptable. * measurable or evaluable disease. * able to perform activities of daily living without considerable assistance * adequate bone marrow, liver and kidney function * must be able to understand the nature of this study and give written informed consent. exclusion criteria: you cannot participate in this study if any of the following apply to you: * age \< 18 years. * cardiac ejection fraction \< 45%. * women who are pregnant or lactating. * patients with meningeal metastases are ineligible. * moderate peripheral neuropathy * history of hypersensitivity reaction to taxotere * males with metastatic breast cancer please note: there are additional inclusion/exclusion criteria. the study center will determine if you meet all of the criteria. if you do not qualify for the trial, study personnel will explain the reasons. if you do qualify, study personnel will explain the trial in detail and answer any questions you may have.
a phase 3, international, multicenter, randomized, double-blind, placebo-controlled, parallel-group efficacy and safety trial of linaclotide administered orally for 12 weeks to patients with irritable bowel syndrome with constipation (ibs-c)

Conditions: Irritable Bowel Syndrome With Constipation (IBS-C)

Summary: this clinical trial is an international, multicenter, randomized, double-blind, placebo-controlled, parallel-group trial comparing one dose of linaclotide to placebo. approximately 800 patients with a diagnosis of ibs-c (modified rome iii criteria) will be randomized at up to 60 trial centers in china, australia, and new zealand. the trial will consist of up to 21 days of screening, 14 to 21 days of pre-treatment, 12 weeks of double-blind treatment, and 2 weeks of follow-up. at the end of the pre-treatment period, patients meeting the entry criteria for this trial will be randomized to one of two double-blind treatment groups: 290 ug linaclotide, or placebo (1:1).


Eligibility criteria:
inclusion criteria: 1. patient has signed an informed consent form(icf). 2. patient must not be pregnant or breastfeeding and agree to use birth control 3. patient meets the colonoscopy requirements defined by the american gastroenterological association guidelines and no clinically-significant laboratory or physical examination findings; 4. patient meets protocol-defined criteria for irritable bowel syndrome with constipation(ibs-c), including stool frequency, straining, stool consistency, abdominal pain, and abdominal discomfort criteria 5. patient meets protocol-defined ediary completion compliance and agrees to refrain from making any new, major life-style changes that may affect ibs-c symptoms exclusion criteria: 1. recent history of mushy or watery stools 2. various medical conditions, medical histories, or family medical histories that would not make the patient a good candidate for the study 3. patient currently has both unexplained and clinically significant alarm symptoms or systemic signs of infection or colitis. 4. surgery to the gastrointestinal tract 5. usage of prohibited medications
multicenter validation of the evergreen myometric strength test for lower extremities (emst-le) in multiple sclerosis: protocol for strength testing and reliability characteristics

Conditions: Multiple Sclerosis

Summary: a cross- sectional study; to assess the intra-rater and inter-rater reliability of a hand-held dynamometer (hhd) in the assessment of lower extremity strength in patients with multiple sclerosis

patients will be tested at two visits separated by 1-21 days. at each visit, the patients would undergo bilateral lower extremity strength assessment by two physical therapists, independently and in the same order. testing would include: hip flexion, knee extension, knee flexion, ankle dorsiflexion testing performed with 1) hhd (three trials recording maximum voluntary force) and 2) manual muscle testing (mmt), british medical research council grade 0-5)

Eligibility criteria:
inclusion criteria: * stable patients with clinically definite ms, aged ≥18, edss of 0-7.5 * clinical stability defined as no ms exacerbation or change in disease modifying therapy for 30 days prior to screening. * edss as described above exclusion criteria: contraindications to strength testing: * inflammatory myopathy * endocarditis, pericarditis or other unstable heart disease * cardiac surgery or myocardial infarction in the last 3 months * decompensated congestive heart failure * severe aortic stenosis * severe pulmonary hypertension * pulmonary embolus or infarction in the last 6 months * uncontrolled hypertension by history or by screening or baseline diastolic blood pressure \>170, or systolic blood pressure \> 105) * marfan's syndrome * pacemaker or cardiac defibrillator * concomitant neurodegenerative neurological disease, such as als or parkinson disease or hemiplegic stroke * females who are pregnant * cognitive deficits that would interfere with the subject's ability to give informed consent or perform study testing. * anticipated treatment with novantrone (mitoxantrone) or cancer chemotherapy or surgical procedure during the study period * painful orthopedic condition affecting the lower extremities * any other serious and/or unstable medical condition
prevalence and incidence of articular symptoms and signs related to psoriatic arthritis in patients with psoriasis severe or moderate with adalimumab treatment

Conditions: Psoriasis; Psoriatic Arthritis

Summary: psoriatic arthritis (psa) is a comorbidity that affects a significant proportion of participants with moderate or severe psoriasis. the purpose of this study was to describe the profile of patients with moderate or severe plaque psoriasis (ps) in colombia and to evaluate adalimumab efficacy and safety profile.

psoriasis is a chronic inflammatory disease affecting 1% to 3% of the population worldwide. a significant portion (5%-40%) of participants with psoriasis develop psa, a chronic inflammatory arthritis that causes progressive joint damage, reduced functionality and increased mortality risk. skin disease typically manifests before arthritis in more than 80% of psa participants, and psoriasis symptoms usually precede joint symptoms by an average of 10 years. participants with psoriasis who have comorbid psa incur substantially increased cost of care and experience greater impairment of physical functioning and quality of life compared with participants with psoriasis alone.

Eligibility criteria:
inclusion criteria: * participant has a documented clinical diagnosis of psoriasis, as determined by participant interview of his/her medical history and confirmation of diagnosis through physical examination by the investigator * participant has indication of psoriasis systemic therapy * if female, participant is either not of childbearing potential, defined as postmenopausal for at least 1 year or surgically sterile (bilateral tubal ligation, bilateral oophorectomy or hysterectomy), or is of childbearing potential and practicing one of the following methods of birth control: * condoms, sponge, foams, jellies, diaphragm or intrauterine device (iud) * contraceptives (oral or parenteral) for three months (90 days) prior to study drug administration * a vasectomized partner * total abstinence from sexual intercourse * able and willing to give written informed consent and comply with the requirements of the study protocol exclusion criteria: * participants who have active infections * participants enrolled in another study or clinical trial * any condition that according to the criteria of the participating investigator represents an obstacle for study conduction and/or participants to an unacceptable risk * history of active tuberculosis (tb), histoplasmosis or listeriosis

Keywords: psoriasis incidence quality of life psoriatic arthritis prevalence
correlation between perioperative eeg features and delirium after general anesthesia

Conditions: Perioperative Period; Anesthetic; Postoperative Cognitive Dysfunction; Postoperative Delirium

Summary: the goal of this observational study is to compare the perioperative eeg characteristics and the incidence of short-term cognitive dysfunction in patients with postoperative delirium and non-postoperative delirium after elderly (\> 65 years old) patients undergoing major gastrointestinal surgery under general anesthesia. the main question it aims to answer are: • the correlation between postoperative cognitive dysfunction and postoperative eeg features was evaluated.• to analyze the correlation between eeg characteristics and clinical risk factors of delirium after major abdominal gastrointestinal surgery under general anesthesia in elderly patients.participants will collect eeg before and after operation and collect the incidence of postoperative cognitive function to explore the mechanism of postoperative delirium and predict postoperative cognitive dysfunction.


Eligibility criteria:
inclusion criteria: 1. education level in primary school or above; 2. age ≥65 years old, gender is not limited; 3. good communication ability, language expression ability, mental state and consciousness state; 4. preoperative simple mental state scale score ≥27 points; 5. no history of craniocerebral diseases; 6. for patients who plan to choose abdominal surgery under general anesthesia, the operation time is expected to be about 2h-4h; 7. asa anesthesia grade i \~ iii; 8. no general anesthesia contraindications; 9. sign informed consent voluntarily; exclusion criteria: 1. relative contraindications of general anesthesia: patients with serious heart and lung function diseases, drug allergy history, etc. 2. patients with a history of mental illness or long-term psychiatric drugs (dementia, schizophrenia), chronic analgesic drug use history, alcoholism history and cognitive dysfunction; 3. any cerebrovascular accident occurred within 3 months, such as stroke, transient ischemic attack (tia), etc. 4. diabetic patients with severe diabetic complications (diabetic ketoacidosis, hyperosmolar coma, various infections, macrovascular disease, diabetic nephropathy); 5. chronic hypoxia and carbon dioxide storage, such as chronic obstructive emphysema; 6. a long history of alcohol abuse; 7. unable to cooperate to complete the test, the patient or family rejected the participant.

Keywords: perioperative period anesthetics postoperative cognitive dysfunction postoperative delirium
hypnosis in internal medecine

Conditions: Hypnosis; Autoimmune Diseases; Medically Unexplained Symptoms

Summary: description of the short and long-term impact of hypnosis sessions for patient having benefited from at least one hypnosis session in internal medicine at the french hospital "groupe hospitalier mutualiste de grenoble", with the help of a qualitative survey made by phone.

the practice of hypnosis has experienced a recent boom in medicine, with a multiplication of its fields of action. regarding internal medicine, the influence of the psyche on the immune system makes the use of hypnosis particularly relevant for autoimmune diseases. medically unexplained symptoms (another important field of internal medicine) are also strongly psychosomatic and thus susceptible to hypnosis. the hypothesis is thus made that hypnosis can bring multiple benefits to internal medicine patients. the main objective of this study is to describe the short and long-term impact of hypnosis sessions for patient having benefited from at least one hypnosis session in internal medicine at the french hospital "groupe hospitalier mutualiste de grenoble", with the help of a qualitative survey made by phone. moreover retrospective medical data concerning these patients will be collected to determine their medical history, their main symptoms et reasons to use hypnosis.

Eligibility criteria:
inclusion criteria: * all consecutive patients who had at least one hypnosis session in internal medicine at the hospital "groupe hospitalier mutualiste de grenoble" between 08/28/2015 (date of the very first hypnosis consultation in internal medicine) and 03/17/2020 (date of confinement due to covid19 in france) exclusion criteria: * patient who had a hypnosis session, but who is not followed for a pathology in internal medicine or in internal medicine with a pneumological orientation

Keywords: internal medicine survey qualitative impact of hypnosis